Al 4° posto Quintiles, al 7° Eli Lilly Italia e all’11° Sanofi. Tra le piccole-medie imprese, 5° posto per Loacker Remedia, 8° per Medtronic Italia Spa. 13 DIC - In tempi di crisi delle ...

Il provvedimento dell’Ente regolatorio concernente la revoca, su rinuncia delle ditte ELI LILLY ITALIA SPA, SANDOZ SPA, SANDOZ GMBH, GERMED PHARMA SRL, NTC SRL, DITTA LABORATORIO FARMACEUTICO SIT ...

Correspondence to Professor Maria A Rocca, Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano 20132, Italy; rocca.mara{at}hsr.it PRLs are considered relatively ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly expects 2024 revenue to be $45 billion, with Mounjaro and Zepbound sales contributing significantly. The company aims to increase Zepbound’s market share, competing with Novo Nordisk ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 116 trades. If we consider the specifics of each ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...